{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:37:16Z","timestamp":1782301036215,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cmi.2026.01.030","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:30:57Z","timestamp":1770481857000},"page":"683-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis"],"prefix":"10.1016","volume":"32","author":[{"given":"Guillaume","family":"Desoubeaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Lemaignen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Vanbiervliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Paccoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Neofytos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lanternier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.01.030_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","article-title":"Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial","volume":"385","author":"Bernard","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.01.030_bib2","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa2020198","article-title":"Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection","volume":"384","author":"Bernard","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.01.030_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae201","article-title":"Antifungal treatment duration in hematology patients with invasive mold infections: a real-life update","volume":"11","author":"Portillo","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.030_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2025.101347","article-title":"Duration of systemic antifungal therapy for patients with invasive fungal diseases: a reassessment","volume":"103","author":"Gressens","year":"2025","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.cmi.2026.01.030_bib19","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.030_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41579-023-00861-x","article-title":"The WHO fungal priority pathogens list as a game-changer","volume":"21","author":"Fisher","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2026.01.030_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.52586\/4955","article-title":"Health threat caused by fungi of medical interest: where are we in 2021?","volume":"26","author":"Desoubeaux","year":"2021","journal-title":"Front Biosci-Landmark"},{"key":"10.1016\/j.cmi.2026.01.030_bib7","doi-asserted-by":"crossref","first-page":"e00920","DOI":"10.1128\/mbio.00920-22","article-title":"Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF network (2012 to 2018)","volume":"13","author":"Bretagne","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.cmi.2026.01.030_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/myc.13496","article-title":"When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?","volume":"65","author":"Roth","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.01.030_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73098-w","article-title":"Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis","volume":"10","author":"Shin","year":"2020","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2026.01.030_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.01.030_bib11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2026.01.030_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.13056","article-title":"Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey","volume":"63","author":"Lanternier","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2026.01.030_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.rcl.2022.01.006","article-title":"Invasive fungal pneumonia in immunocompromised patients","volume":"60","author":"Godoy","year":"2022","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.cmi.2026.01.030_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.030_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10096-013-1944-3","article-title":"Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species","volume":"33","author":"Drgona","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.030_bib17","doi-asserted-by":"crossref","first-page":"230086","DOI":"10.1183\/16000617.0086-2023","article-title":"Atypical imaging patterns during lung invasive mould diseases: lessons for clinicians","volume":"32","author":"Casutt","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cmi.2026.01.030_bib18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.01.030_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1128\/JCM.00750-11","article-title":"Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients","volume":"50","author":"Bergeron","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.01.030_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00394-24","article-title":"Dynamics and prognostic value of plasma cell-free DNA PCR in patients with invasive aspergillosis and mucormycosis","volume":"62","author":"Moreno","year":"2024","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2026.01.030_bib16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26000546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:45:20Z","timestamp":1775843120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26000546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1198743X26000546"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.030","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}